Amgen's Xgeva matches zoledronic acid in phase 3 trial in multiple myeloma-related bone complica
A phase 3 study assessing Amgen’s Xgeva (denosumab) compared to zoledronic acid (ZA) for the prevention of bone complications in newly diagnosed multiple myeloma (MM) patients met its primary endpoint.
